NSAIDs for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography：Ready for prime time

Acute pancreatitis is the most common and the most fearful complication of endoscopic retrograde cholangiopancreatography （ERCP）.Prevention of post-ERCP pancreatitis has therefore been of great interest to endoscopists performing ERCP procedures.So far,only pancreatic duct stenting during ERCP and r...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 18; no. 30; pp. 3936 - 3937
Main Author Parsi, Mansour A
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Co., Limited 14.08.2012
Subjects
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Cholangiopancreatography, Endoscopic Retrograde - adverse effects
Field Of Vision
Humans
Pancreatitis - etiology
Pancreatitis - prevention & control
Risk Factors
内镜
急性胰腺炎
时间
胆管
造影
非甾体抗炎药
非甾体类抗炎药
预防
Pancreatic stents
Endoscopic retrograde cholangiopancreatography
Post-endoscopic retrograde cholangiopancreatography pancreatitis
Pancreatitis
Non-steroidal anti-inflammatory drugs
Online AccessGet full text

Cover

More Information
Summary:Acute pancreatitis is the most common and the most fearful complication of endoscopic retrograde cholangiopancreatography （ERCP）.Prevention of post-ERCP pancreatitis has therefore been of great interest to endoscopists performing ERCP procedures.So far,only pancreatic duct stenting during ERCP and rectal administration of a non-steroidal anti-inflammatory drug （NSAID） prior to or immediately after ERCP have been consistently shown to be effective for prevention of post-ERCP pancreatitis.This commentary focuses on a short discussion about the rates,mechanisms,and risk factors for post-ERCP pancreatitis,and effective means for its prevention with emphasis on the use of NSAIDs including a recent clinical trial published in The New England Journal of Medicine by Elmunzer et al.
Bibliography:14-1219/R
Acute pancreatitis is the most common and the most fearful complication of endoscopic retrograde cholangiopancreatography （ERCP）.Prevention of post-ERCP pancreatitis has therefore been of great interest to endoscopists performing ERCP procedures.So far,only pancreatic duct stenting during ERCP and rectal administration of a non-steroidal anti-inflammatory drug （NSAID） prior to or immediately after ERCP have been consistently shown to be effective for prevention of post-ERCP pancreatitis.This commentary focuses on a short discussion about the rates,mechanisms,and risk factors for post-ERCP pancreatitis,and effective means for its prevention with emphasis on the use of NSAIDs including a recent clinical trial published in The New England Journal of Medicine by Elmunzer et al.
Endoscopic retrograde cholangiopancreatography Pancreatitis Post-endoscopic retrograde cholangiopancreatography pancreatitis Pancreatic stents Non-steroidal anti-inflammatory drugs
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: Parsi MA contributed entirely to this manuscript.
Telephone: +1-216-4454880 Fax: +1-216-4446284
Correspondence to: Mansour A Parsi, MD, MPH, Head, Section for Therapeutic and Pancreatobiliary Endoscopy, Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, United States. parsim@ccf.org
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v18.i30.3936